News

Dr Morris joins Cyberonics from InnerPulse, a privately held cardiology-focused medical technology company in North Carolina, where he has served as director of program management and operations since

Atrium Biosurgery is engaged in the development of advancements in biological, mechanical and therapeutic solutions for soft tissue healing following trauma, surgery and or other interventional procedures that

The Phase IIb trial is anticipated to enroll about 400 treatment-naive, genotype-1 or genotype 4 hepatitis C virus (HCV)-infected patients. The trial will evaluate the dose and duration

As a result of the designation, a new drug application (NDA) for Soliris would receive priority review from the Japanese regulatory authorities once it is submitted, and the

Clarus Ventures, a life sciences venture capital firm, led the round and was joined with a follow-on investment by FatBoy Capital. In conjunction with the financing, Kurt Wheeler

Under the terms of the agreement, current International Bio Immune Systems (IBS) shareholders will have the opportunity to become shareholders in Neogenix. Additional terms of the transaction have

Enrollment is now closed in this study to assess the safety and efficacy of Augment for the treatment of foot and ankle fusions as compared to autograft, the

According to BioSeek, under the collaboration, it will, over the next year, both carry out broad-based profiling of selected UCB new chemical and biological entities, and guide lead

Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s autonomously diversifying library (ADLib) system and will apply the system to assessment of target proteins and